ODTX

16.8308.23%
EL

Eicke Latz

Scientific Co-Founder

Prof. Eicke Latz, MD, PhD., is a Scientific Co-Founder of Odyssey Therapeutics, Inc. He has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate immunity and inflammation into novel therapeutic approaches, with programs advancing into clinical development and leading to successful exits and initial public offerings. Through his biopharma ventures, Dr. Latz is bridging fundamental disease biology insights to therapeutic innovation, unmet medical needs and value creation. Dr. Latz is also a highly respected scientific and organizational leader. His leadership extends across academia medical centers, biopharma industry and governmental advisory work on venture formation and scaling, to senior advisory roles with major pharmaceutical companies. Prof. Latz is Director and Scientific Co-founder at DiosCURE Therapeutics SE. He is Co-Founder and Member of Scientific Advisory Board of IFM Therapeutics, Inc. Prof. Latz is an Adjunct Professor at the Centre for Molecular Inflammation Research at the Norwegian Technical University in Trondheim and heads a research group at the German Center for Neurodegenerative Diseases (DZNE) in Bonn. He serves as Assistant Professor of Department of Infectious Diseases and Immunology of the University of Massachusetts. He joined the UMass Faculty in 2006. He serves as Scientific Advisor of Invion Limited. He founded the Institute of Innate Immunity at the University of Bonn in 2010. His research focuses on identifying the most proximal mechanisms of innate immune activation in chronic inflammatory diseases. His laboratory studies the mechanisms involved in inflammasome activation and regulation, investigates how nucleic acids are sensed by Toll-like receptors and cytosolic sensors and performs systems approaches to decipher innate immune signaling pathway regulation. He has extensive experience in the field of innate immunity and Toll-like receptor biology. He was faculty at the University of Bonn. He worked on the molecular recognition of bacterial lipopolysaccharides in the Laboratory of Molecular Sepsis Research at the Humboldt University in Berlin. He developed drug-screening assays for the development of TLR antagonists. He serves as a Member of Scientific Advisory Board at Opsona Therapeutics Limited. He has published seminal work in innate immunity in the highest ranking scientific journals and received numerous awards for his work. He is listed in the World’s Most Influential Minds by Thompson Reuters and is a highly cited scientist in immunology in 2014 and 2015. He studied Medicine in Göttingen and Berlin and worked as an intensive care physician at the Charité Hospital in Berlin. Prof. Latz graduated with an MD and PhD degree from the Free University and Humboldt University in Berlin, Germany respectively. He received Clinical training in the field of Intensive Care Medicine at the Charité University Medical Center in Berlin. He received Postdoctoral Research training in the pharmaceutical industry at Boston University and UMass Medical School in the Golenbock laboratory in 2000.

Positions